In a phase I trial, the menin inhibitor revumenib achieves a complete response in 18 patients with AML, revealing a cause of resistance to this potential new treatment.
Acute myeloid leukemia. Image: ATLAS OF HAEMATOLOGICAL CYTOLOGY.
Editor-in-Chief Prize-winning journalist with over 20 years of international news experience. Alexandra leads the editorial team, ensuring every story meets the highest standards of accuracy and journalistic integrity.
